# Cagrilintide vs Semaglutide: Differences, Weight Loss Results & Which to Consider **By TelosRX Clinical Team** · 2026-09-01 **Cagrilintide and semaglutide target different hunger-signaling pathways — one mimics amylin, the other activates GLP-1 receptors. REDEFINE trial data shows the combination produced greater average weight reduction than semaglutide alone. Access to either requires medical approval by a licensed provider. [TelosRX](https://telosrx.com) offers asynchronous evaluations.** If you follow obesity medicine research, 2025 was the year cagrilintide moved from a footnote to a headline. Novo Nordisk's REDEFINE program published Phase 3 trial results showing the combined therapy — branded CagriSema — outperformed semaglutide alone by a meaningful margin. That triggered a flood of patient questions: what's the difference, which should I ask about, and is any of this available? This article breaks it down: mechanisms, trial data, side effects, and what "which to consider" actually means in a clinical context. ## What Is Cagrilintide? Cagrilintide is a long-acting synthetic amylin analog. Amylin is a hormone your pancreatic beta cells release alongside insulin — it signals the brain to slow gastric emptying and reduce appetite. Cagrilintide mimics and extends that signal with once-weekly subcutaneous dosing. It targets a receptor pathway entirely separate from GLP-1. That's the key point: it's not just a different drug in the same class. It's a different mechanism layered on top of what GLP-1 agonists already do. Cagrilintide is not FDA-approved for any indication. It is not commercially available as a standalone product. Any clinical access to it would require a licensed provider's evaluation and, if appropriate, a prescription for a compounded formulation under federal compounding regulations — which is distinct from any FDA-approved drug. ## What Is Semaglutide? Semaglutide is a GLP-1 receptor agonist — the same class as liraglutide, but with a longer half-life that enables weekly dosing. It mimics glucagon-like peptide-1, a gut-released hormone that slows gastric emptying, signals satiety in the brain, and stimulates insulin secretion in response to meals. Brand-name semaglutide (Ozempic for T2D, Wegovy for obesity) is FDA-approved. Compounded semaglutide — prepared by a licensed pharmacy under federal compounding regulations — is not FDA-approved but has been widely accessible through telehealth pharmacies. See [TelosRX's compounded semaglutide guide](https://www.telosrx.com/blogs/glp1/compounded-semaglutide-telehealth-2026) for context on how access works today. ## Cagrilintide vs Semaglutide: Side-by-Side Comparison Feature Cagrilintide Semaglutide **Drug class** Amylin receptor agonist GLP-1 receptor agonist **Target pathway** Amylin / CGRP receptor GLP-1 receptor **Dosing** Once-weekly subcutaneous injection Once-weekly subcutaneous injection **FDA approval** Not approved (investigational) Approved (brand); compounded = not FDA-approved **Mean weight loss (monotherapy, trials)** ~8–10% body weight ~13–15% body weight (Wegovy 2.4 mg) **Mean weight loss (CagriSema combo)** ~20.4% (REDEFINE 1, non-T2D adults) **Glycemic effect** Moderate via amylin pathway Strong; approved for T2D (Ozempic) **Top side effects** Nausea, injection-site reactions Nausea, vomiting, diarrhea, constipation **Commercial availability** Not commercially available Brand-name + compounded (Rx required) ## REDEFINE Trial Results: What the Data Found The REDEFINE program is the largest clinical dataset directly comparing CagriSema to semaglutide. REDEFINE 1 enrolled adults with overweight or obesity but without type 2 diabetes. At 68 weeks, mean body weight change was **−20.4%** with CagriSema versus −3.0% with placebo — roughly 5–8 percentage points more than semaglutide monotherapy at equivalent doses. Full results are available in _The New England Journal of Medicine_: [REDEFINE 1](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081) and [REDEFINE 2](https://www.nejm.org/doi/full/10.1056/NEJMoa2502082). REDEFINE 2 focused on adults with type 2 diabetes. Of CagriSema participants, 74% achieved an HbA1c of ≤6.5% by week 68 — compared to 15.9% on placebo. A [2025 meta-analysis on PubMed](https://pubmed.ncbi.nlm.nih.gov/41834765/) reviewing CagriSema versus semaglutide confirmed the combination produced meaningful additional weight reduction across trials. These are population-level trial averages, not individual outcome guarantees. Individual results vary based on metabolic health, adherence, dose titration, and many other factors. ## Side Effects Compared Both agents slow gastric emptying, so nausea is the most common complaint with each. When combined, the GI side-effect rate climbed: REDEFINE 1 reported gastrointestinal adverse events in 79.6% of CagriSema participants (mostly mild-to-moderate and transient) versus lower rates with semaglutide alone. - **Semaglutide alone:** nausea, vomiting, diarrhea, constipation — well-characterized from large Wegovy/Ozempic trials - **Cagrilintide alone:** nausea, injection-site reactions, reduced appetite - **CagriSema combo:** additive GI effects; more injection-site reactions than semaglutide alone Provider-guided dose titration — starting low and increasing slowly — is the standard approach to managing tolerability with both agents. Any reported side effect warrants a conversation with your prescribing provider. ## Which to Consider? This is a clinical decision, not a self-selection exercise. Semaglutide has a far longer track record of accessible compounded prescribing. Cagrilintide in any form is not commercially available and would require a compounding pharmacy able to prepare it under federal regulations — and even then, only with a licensed provider's evaluation and provider-issued prescription. If you're exploring weight management options, the practical path starts with an asynchronous health evaluation. A licensed provider reviews your history, any metabolic labs, and your goals — then determines what (if anything) is clinically appropriate. That's true whether you're asking about semaglutide, tirzepatide, or emerging compounds like cagrilintide. Read how that works at [TelosRX's GLP-1 comparison guide](https://www.telosrx.com/blogs/glp1/tirzepatide-vs-semaglutide-compounded-glp1-comparison), or review [the detailed REDEFINE trial breakdown](https://www.telosrx.com/blogs/glp1/cagrilintide-weight-loss-redefine-trial-guide) for the full cagrilintide dataset. Start your private evaluation at [TelosRX](https://telosrx.com) — no video call required. ## Frequently Asked Questions ### What is the difference between cagrilintide and semaglutide? Semaglutide is a GLP-1 receptor agonist that mimics a gut hormone to reduce appetite and slow digestion. Cagrilintide is an amylin analog that works on a different receptor pathway — targeting satiety signals originating in pancreatic amylin biology. The two complement each other, which is why the combination (CagriSema) showed additive effects in Phase 3 trials. ### Is cagrilintide available in the US in 2026? CagriSema as a branded combination therapy is not FDA-approved as of mid-2026. Cagrilintide as a compounded peptide is also not FDA-approved. Access to any compounded formulation requires evaluation and a provider-issued prescription through a licensed compounding pharmacy. Your eligibility depends on your individual health profile as reviewed by a licensed provider. ### Is CagriSema more effective than semaglutide alone? REDEFINE trial data suggests it is, on average: CagriSema produced approximately 20.4% mean body weight reduction versus roughly 13–15% with semaglutide alone at similar doses. However, the combination also carried a higher rate of gastrointestinal side effects. Clinical appropriateness depends on the individual — a licensed provider must evaluate whether the benefit-risk profile fits your situation. ### What are the side effects of CagriSema? The most commonly reported side effects in REDEFINE trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation — affecting approximately 79.6% of CagriSema participants, most mild to moderate. Injection-site reactions were also higher with the combination. Slow dose titration under provider guidance is standard practice for managing tolerability. ### Can I get cagrilintide through a telehealth pharmacy? Any compounded peptide medication — including cagrilintide — requires evaluation by a licensed provider and a provider-issued prescription. TelosRX's evaluation process is fully asynchronous: you complete a health questionnaire, a licensed provider reviews it, and if clinically appropriate, medication ships from a licensed pharmacy. Approval is not guaranteed. ### How does semaglutide compare to CagriSema for type 2 diabetes? Semaglutide (Ozempic) has FDA-approved indications for type 2 diabetes. In REDEFINE 2, the CagriSema combination achieved HbA1c ≤6.5% in 74% of T2D participants versus 15.9% on placebo — a substantial glycemic benefit. CagriSema is not FDA-approved for any indication. Any medication decision for T2D management requires a prescribing provider's evaluation. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ Start your private evaluation at [TelosRX](https://telosrx.com). --- > Source: [Telos RX](https://www.telosrx.com/blogs/glp1/cagrilintide-vs-semaglutide-comparison)